Semaglutide + Cagrilintide
This pairing is essentially a preview of Novo Nordisk's CagriSema, which posted ~23% weight loss in phase 3 — approaching tirzepatide-plus territory. Semaglutide drives satiety through the incretin axis; cagrilintide adds amylin-pathway fullness (slower gastric emptying, meal-size reduction) through a completely separate receptor. Different levers, additive effect.
Components & typical mixing
| Peptide | Typical dose | Typical mix | Units/dose |
|---|---|---|---|
| Semaglutide | 250 mcg–2.4 mg, 1x weekly, titrated up over months | 5 mg + 2 ml | 20 units = 500 mcg |
| Cagrilintide | 250 mcg–2.4 mg, 1x weekly | 5 mg + 2 ml | 20 units = 500 mcg |
How the protocol is typically run
- →Both are once-weekly subcutaneous injections, commonly taken the same day.
- →Trial structure titrated both in parallel up to 2.4 mg + 2.4 mg weekly; community protocols typically run cagrilintide at or below the semaglutide dose.
- →Titration is slow on purpose — each step holds ~4 weeks. Stacking does not mean skipping ramp steps on either compound.
- →Separate vials, separate reconstitution; they can be injected at the same sitting but are not mixed in one vial.
Cautions
GI side effects are the binding constraint — nausea from two satiety mechanisms compounds fast if titration is rushed. This stack deserves medical supervision more than any other on this site: it's a pharmaceutical-grade intervention in research packaging.
Other stacks
Educational reference describing commonly published protocols — not medical advice. Most compounds referenced are research chemicals without approval for human use.